Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.

Substance abuse treatment, prevention, and policy - 12 Jan 2007

Huckans Marilyn S, Loftis Jennifer M, Blackwell Aaron D, Linke Alex, Hauser Peter

Abstract excerpt

BACKGROUND: Individuals with substance use disorders (SUDs) are at increased risk for hepatitis C viral infection (HCV), and few studies have explored their treatment responses empirically. The objective of this study was to assess interferon alpha therapy (IFN) completion and response rates among patients with HCV who had a history of comorbid SUDs. More data is needed to inform treatment strategies and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Comorbidity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Substance-Related Disorders

Share to United States

Share to Veterans

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 17222348
DOI: 10.1186/1747-597X-2-4
PMCID: PMC1781072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.PMID 17222348Read ↗

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.Semantic proximity Read ↗

Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.Semantic proximity Read ↗

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy: A National Observational Cohort StudySemantic proximity Read ↗

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.Semantic proximity Read ↗

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Semantic proximity Read ↗

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Semantic proximity Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.Semantic proximity Read ↗

Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.Semantic proximity Read ↗

Predictors of response of US veterans to treatment for the hepatitis C virus.Semantic proximity Read ↗

High rates of early treatment discontinuation in hepatitis C-infected US veterans.Semantic proximity Read ↗

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.